Abstract:

The administration of certain cancer therapies can be associated with the development of cardiovascular toxicity or complications. This spectrum of toxicities is broad and requires nuanced approaches for prevention, identification, and management. This Expert Panel summarizes the consensus of opinions of diverse healthcare professionals on several key areas. 1) Cardio protection involves strategies aimed at the primary prevention of cancer therapy–related cardiovascular toxicity (CTR-CVT). 2) Surveillance entails monitoring for CTR-CVT during cancer therapy. 3) Permissive cardiotoxicity refers to the informed continuation of cancer therapy in the presence of cardiovascular toxicity, along with the implementation of mitigating cardiovascular treatments. 4) Special considerations include the invasive management of severe cardiovascular disease in patients receiving treatments for advanced cancer and the exploration of drug–drug interactions in cardio-oncology.

JACC CardioOncology Editor-in-Chief and CME Editor
Bonnie Ky, MD, MSCE, FACC

Author
Megan Pelter, MD

Important Dates

Date of Release: December 17, 2024
Term of Approval/Date of CME/MOC Expiration: December 16, 2025